Generex Biotechnology Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNBT research report →
Price Chart
About the company
Founded in 1983 and headquartered in Miramar, Florida, Generex Biotechnology Corporation initially specialized in the delivery of large molecule drugs into the oral cavity via a portable aerosol applicator for use in Canada and the United States, notably offering Generex Oral-lyn, an oral insulin product. The company also had a significant focus on oncology, developing AE37, a synthetic peptide vaccine that had completed Phase IIb clinical trials aimed at stimulating a potent and specific immune response against HER-2/neu oncogenes in breast and prostate cancer patients. Beyond therapeutics, Generex was involved in the development, manufacturing, and distribution of rapid point-of-care in-vitro medical diagnostics for a spectrum of infectious diseases, including HIV, tuberculosis, malaria, and hepatitis, providing both test kits and cassettes.
- CEO
- Joseph Moscato
- IPO
- 1998
- Employees
- 15
- HQ
- Miramar, FL, US
Get TickerSpark's AI analysis on GNBT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.43
- Div Yield
- 0.00%
- Gross Margin
- 78.24%
- Op Margin
- -673.54%
- Net Margin
- -1252.72%
- ROE
- 216.76%
- ROIC
- -88.91%
Latest fiscal year · YoY change
- Revenue
- $2.66M-57.1%
- Gross Profit
- $2.08M+0.8%
- Op Income
- $-17,923,000
- Net Income
- $-33,335,000-256.9%
- EPS
- $-0.46-228.6%
- OCF Growth
- +36.1%
- FCF Growth
- +38.1%
- 52W High
- $0.14
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- -0.06
- RSI (14)
- 44
- Avg Volume
- 18.59K
No earnings-call transcripts are available for GNBT yet.
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 27, 19 | Prioletti Mark Joseph SE | other | 0 |
| May 14, 19 | Salvo Lawrence Anthony Sr | other | 0 |
| Dec 4, 18 | Haines Harold Gray | buy | 945 |
| Dec 4, 18 | Haines Harold Gray | buy | 555 |
| Dec 7, 18 | Haines Harold Gray | buy | 8,000 |
| Dec 7, 18 | Haines Harold Gray | buy | 300 |
| Oct 3, 18 | Ro Andrew | other | 4,500 |
| Oct 3, 18 | Purcell Richard David Jr. | other | 4,500 |
| Oct 3, 18 | MCGEE BRIAN | other | 1,000 |
| Oct 3, 18 | Lyman Gary Herbert | other | 1,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GNBT coverage
Recent articles, reports, and earnings notes.
No research on GNBT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNBT report →Contrasting Zymeworks (NASDAQ:ZYME) and Generex Biotechnology (OTCMKTS:GNBT)
defenseworld.net · Feb 6
NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm
globenewswire.com · Jun 22
Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient Monitoring (RPM) Services
globenewswire.com · May 6
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at 9:00 AM
globenewswire.com · May 4
Last Chance for Children is Proud to Announce its Partnership with Generex Biotechnology & NuGenerex Immuno-Oncology to SAFELY and EFFECTIVELY Vaccinate Children and Pregnant Women
globenewswire.com · Apr 8
Generex Biotechnology Announces Shareholder Conference Call Scheduled for Thursday May 6, 2021
globenewswire.com · Mar 31
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine™ Development Program
globenewswire.com · Feb 24
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021 at 9:00 AM
globenewswire.com · Feb 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.